www.cdc.gov: Lighthouse — 第 2026-W40 週

Google Lighthouse(独自のヘッドレス Chrome)でサンプリングされた 166 ページ。スコアは 0〜100(高いほど良い)、指標は Core Web Vitals です。ダウンロード： CSV(ページ別スコア) · JSON(AI 対応、推奨事項を含む) · 優先ページ CSV · 優先ページ JSON.

傾向

17 週間にわたる Lighthouse カテゴリスコア

週別の Lighthouse カテゴリスコア
週	パフォーマンス	アクセシビリティ	ベストプラクティス	SEO
2026-W24	82	100	100	100
2026-W25	77	100	96	100
2026-W26	78	100	96	100
2026-W27	80	100	100	100
2026-W28	82	100	96	100
2026-W29	82	100	96	100
2026-W30	84	100	96	100
2026-W31	82	100	96	100
2026-W32	82	100	96	100
2026-W33	77	100	96	100
2026-W34	79	100	96	100
2026-W35	83	100	96	100
2026-W36	86	100	96	100
2026-W37	80	100	96	100
2026-W38	83	100	96	100
2026-W39	80	99	100	100
2026-W40	82	100	100	100

History & Trends → Severity, Lighthouse and other measures across 17 weeks.

パフォーマンスへの影響

How far pages fall short of Google's "good" benchmarks: Largest Contentful Paint ≤ 2.5s and page weight ≤ 1.6 MB. Lower is better.

Avg extra LCP over 2.5s: 3.5s 105/165 pages over
Avg extra weight over 1.6 MB: 3.94 MB 142/193 pages over

Set page_loads_per_week for this target to also estimate total wasted time and data (the way daily-dap uses traffic counts).

サンプルページの中央値

パフォーマンス: 82/100
アクセシビリティ: 100/100
ベストプラクティス: 100/100
SEO: 100/100
エージェントによるブラウジング: 94/100
Largest Contentful Paint(LCP): 3.0s
First Contentful Paint(FCP): 1.6s
Speed Index: 4.3s
Total Blocking Time(合計ブロック時間): 0.2s
Cumulative Layout Shift(累積レイアウトシフト): 0.018

推奨事項

見出しスコアを超えて、Lighthouse が 166 件のサンプルページで指摘した問題。カテゴリ別にグループ化され、影響するページ数で順位付けされています。推定削減量(転送バイト数または読み込み時間)は、利用可能な場合は Lighthouse 自身の推定です。アクセシビリティ監査は意図的に省略されています。アクセシビリティページの axe-core の検出と重複するためです。

パフォーマンス

Lighthouse によるパフォーマンスの推奨事項。影響を受けたサンプルページ順。
推奨事項	ページ	推定削減量
Reduce unused JavaScript	164/166	24.9 MB · 28.9s
JavaScript execution time	163/166	42.8s
Minimize main-thread work	159/166	37.1s
Network dependency tree	158/166	—
Use efficient cache lifetimes	148/166	418.6s
Time to Interactive	140/166	—
Render-blocking requests	126/166	77.8s
Reduce unused CSS	125/166	9.8 MB · 54.5s
Minify JavaScript	107/166	4.4 MB · 10.9s
Largest Contentful Paint	105/166	—
Font display	99/166	5.5s
Speed Index	99/166	—
Avoid multiple page redirects	90/166	70.8s
Improve image delivery	61/166	120.7s
Total Blocking Time	56/166	—
LCP request discovery	52/166	—
Max Potential First Input Delay	51/166	—
Layout shift culprits	50/166	—
First Contentful Paint	49/166	—
Forced reflow	26/166	—
Document request latency	16/166	1.4s
Legacy JavaScript	13/166	1.9s
Page prevented back/forward cache restoration	8/166	—
Initial server response time was short	4/166	0.3s
Minify CSS	2/166	30 KB

ベストプラクティス

Lighthouse によるベストプラクティスの推奨事項。影響を受けたサンプルページ順。
推奨事項	ページ	推定削減量
Browser errors were logged to the console	50/166	—
Serves images with low resolution	44/166	—
Page lacks the HTML doctype, thus triggering quirks-mode	40/166	—
Issues were logged in the `Issues` panel in Chrome Devtools	37/166	—
Does not use HTTPS	32/166	—
Displays images with incorrect aspect ratio	22/166	—
Charset declaration is missing or occurs too late in the HTML	19/166	—
Missing source maps for large first-party JavaScript	3/166	—

SEO

Lighthouse による SEO の推奨事項。影響を受けたサンプルページ順。
推奨事項	ページ	推定削減量
Document does not have a meta description	53/166	—
Image elements do not have `[alt]` attributes	32/166	—
Links do not have descriptive text	15/166	—
Links are not crawlable	2/166	—

エージェント対応(AI 対応度)

Lighthouse によるエージェント対応(AI 対応度) の推奨事項。影響を受けたサンプルページ順。
推奨事項	ページ	推定削減量
WebMCP tools registered	165/166	—
WebMCP form coverage	165/166	—
WebMCP schemas are valid	165/166	—
llms.txt follows recommendations	165/166	—
Cumulative Layout Shift	52/166	—
Accessibility tree is not well-formed	39/166	—

エージェント対応スコアの意味

エージェント対応(AI 対応度)スコアは Google Lighthouse(13.4 以降)の新機能です。これは、人々が行政サービスを見つけて利用する方法をますます仲介するツールである AI エージェントとアシスタントにとって、ページがどれだけ機能するかを測定します。llms.txt ファイル(言語モデル向けの機械可読ガイド)、有効な構造化データ、エージェントが解析できる適切に構成されたアクセシビリティツリー、WebMCP のツール/フォームの記述などをチェックします。スコアが高いほど、AI アシスタントがそのページを理解し、市民に代わってタスクを正しく完了できる可能性が高まります。

これは実験的で進化中です。コンプライアンス要件ではなく、将来を見据えたシグナルとして扱ってください。サンプルページの中央値: 94/100.

サンプルページで見つかった不足: WebMCP tools registered (165), WebMCP form coverage (165), WebMCP schemas are valid (165), llms.txt follows recommendations (165), Cumulative Layout Shift (52), Accessibility tree is not well-formed (39).

ページ別の結果

サンプルページごとの Lighthouse スコアと Core Web Vitals(2026-W40)。エージェント対応 = 実験的なエージェントブラウジングスコア。PWA / オフライン対応は標準タブで追跡されます(Lighthouse 12 以降は PWA カテゴリが削除されました)。 — 列見出しをクリックして並べ替え

/acute-bronchitis/about/index.html	90	100	100	100	100	1.2s	3.0s	4.3s	0.2s	0.003
/vaccines/hcp/by-disease/hib.html	89	100	100	100	96	1.8s	2.4s	4.4s	0.2s	0.089
/mmwr/preview/mmwrhtml/00053877.htm	100	62	63	83	100	1.3s	1.3s	1.3s	0.1s	0
/national-asthma-control-program/site.html	95	100	100	100	100	1.2s	2.0s	3.8s	0.2s	0.013
/niosh/publications/numbered/2014-149.html	89	100	100	100	47	1.3s	2.9s	4.7s	0.1s	0.08
/pcd/issues/2009/jan/08_0020_fr.htm	99	66	67	83	50	1.1s	1.7s	1.1s	0.1s	0
/mmwr/preview/mmwrhtml/ss5709a3.htm	89	59	67	83	100	1.1s	3.8s	1.3s	0.0s	0
/PCD/issues/2010/may/09_0164.htm	99	70	67	83	50	1.3s	1.4s	1.3s	0.1s	0
/niosh-rtecs/KN657890.html	74	96	100	100	36	2.1s	3.9s	4.3s	0.2s	0.168
/mmwr/preview/mmwrhtml/mm5446md.htm	100	59	62	83	100	0.8s	1.8s	0.8s	0.1s	0
/diabetes/es/diabetes-complications/la-diabetes-y-la-salud-oral.html	82	100	100	100	100	1.7s	3.4s	6.0s	0.2s	0.003
/niosh/fedreg.html	79	100	100	100	98	1.7s	4.0s	5.8s	0.2s	0.071
/mmwr/mmwr_additional_resources.html	32	100	96	100	51	2.2s	8.6s	4.3s	0.6s	1.008
/mmwr/preview/mmwrhtml/rr5217a1.htm	97	62	65	83	100	1.4s	2.1s	1.4s	0.1s	0
/antimicrobial-resistance-laboratory-networks/es/site.html	84	100	100	100	100	1.2s	2.0s	4.8s	0.5s	0.003
/diabetes/living-with/mental-health.html	76	100	100	100	96	1.6s	4.4s	4.8s	0.2s	0.089
/lead-prevention/php/data/nhanes.html	89	100	100	100	100	1.6s	2.9s	4.9s	0.2s	0.003
/mmwr/preview/mmwrhtml/mm5312a5.htm	100	59	62	83	100	1.2s	1.2s	1.2s	0.0s	0
/mmwr/volumes/71/wr/mm7101a2.htm	65	95	96	100	76	2.3s	4.0s	2.3s	0.3s	0.241
/media/es/releases/2024/m1924-casograve-h5n1.html	93	100	100	100	100	1.6s	2.3s	5.0s	0.1s	0.032
/bird-flu/about/avian-influenza-type-a.html	66	91	100	85	50	2.2s	15.3s	6.4s	0.1s	0.009
/howrightnow/gratitude/index.html	46	100	96	100	54	2.1s	33.1s	2.4s	0.2s	0.653
/muscular-dystrophy/hcp/clinical-overview/index.html	75	100	100	100	91	1.6s	3.6s	4.8s	0.3s	0.132
/diabetes/signs-symptoms/index.html	77	100	100	100	85	1.6s	3.7s	5.1s	0.1s	0.174
/polaris/php/economics/cost-analysis.html	78	100	100	100	84	1.2s	3.6s	4.1s	0.2s	0.175
/pcd/issues/2005/apr/04_0142o_zht.htm	99	66	65	83	50	0.8s	0.9s	0.8s	0.1s	0
/stophivtogether/spanish/preparado/index.html	40	90	92	92	30	2.0s	7.3s	7.6s	0.7s	0.209
/niosh/fedreg.html	81	100	100	100	96	1.2s	3.9s	4.0s	0.2s	0.092
/niosh/idlh/107051.html	81	100	100	100	69	1.8s	2.0s	1.9s	0.2s	0.307
/mmwr/volumes/71/wr/mm7138e2.htm	61	98	96	100	71	2.3s	4.1s	2.3s	0.4s	0.287
/brfss/acbs/2017/multiple_year/acbs_prevalence_15-17_table2a.html	39	96	100	92	54	2.7s	6.6s	5.7s	0.3s	0.658
/cannabis/health-effects/cannabis-use-disorder.html	95	100	100	100	100	1.2s	1.4s	5.0s	0.1s	0.046
/laboratory-systems/php/about	95	100	100	100	100	1.2s	2.0s	3.9s	0.2s	0.004
/mmwr/volumes/70/wr/mm7040e3.htm	33	98	96	100	100	6.7s	34.3s	10.6s	1.1s	0
/mmwr/preview/mmwrhtml/00000883.htm	100	55	63	83	100	1.2s	1.3s	1.2s	0.1s	0
/pcd/issues/2007/oct/07_0021.htm	98	70	65	83	50	1.0s	1.1s	1.0s	0.2s	0
/faca/committees/acip.html	94	100	100	100	100	1.6s	2.3s	4.0s	0.2s	0.016
/nchs/injury/injury_links.htm	68	100	96	92	68	2.3s	3.1s	2.3s	0.3s	0.328
/acip/evidence-to-recommendations/pneumo-PCV15-PPSV23-age-based-etr.html	92	100	100	100	100	1.7s	2.4s	4.7s	0.2s	0.014
/pcd/issues/2005/jan/04_0105.htm	100	66	67	83	50	1.2s	1.4s	1.2s	0.1s	0
/flu-vaccines-work/index.html	65	91	100	85	50	2.2s	15.2s	6.6s	0.2s	0.009
/mmwr/preview/mmwrhtml/mm6013a2.htm	98	79	85	92	50	1.4s	2.2s	1.4s	0.1s	0
/covid/vaccines	88	100	100	100	96	1.2s	2.9s	4.9s	0.1s	0.094
/leishmaniasis/about/index.html	86	100	100	100	93	1.2s	3.0s	4.8s	0.1s	0.117
/niosh/bulletin/2021/opioids-in-construction.html	91	100	100	100	96	1.5s	1.6s	5.6s	0.1s	0.094
/hepatitis-b/about/index.html	67	91	100	85	50	2.2s	12.4s	6.5s	0.1s	0.009
/early-care-education/php/data-research/index.html	84	100	100	100	100	1.5s	3.5s	5.5s	0.1s	0.035
/dengue/stories/integrated-mosquito-control.html	68	100	100	100	94	1.2s	6.5s	5.7s	0.1s	0.109
/pinkbook/hcp/table-of-contents	88	100	100	100	100	1.7s	2.7s	5.0s	0.2s	0.002
/niosh/docs/wp-solutions/2024-123	87	100	100	100	50	1.7s	3.5s	4.5s	0.1s	0.004
/overdose-resources/index.html	46	100	100	92	62	1.2s	35.9s	9.1s	0.1s	0.411
/mmwr/preview/mmwrhtml/mm6309a4.htm	83	79	85	92	50	1.8s	4.4s	2.6s	0.1s	0
/chickenpox/hcp/clinical-overview/index.html	64	100	100	100	100	1.4s	11.4s	6.0s	0.3s	0.044
/mmwr/preview/mmwrhtml/mm6249a5.htm	95	78	85	92	50	1.8s	2.7s	1.8s	0.1s	0
/nchs/products/databriefs/db407.htm	28	100	96	100	57	5.0s	31.4s	5.0s	0.5s	0.53
/niosh/idlh/110430.html	70	100	100	100	65	2.7s	3.0s	2.7s	0.2s	0.357
/von-willebrand/about/index.html	73	100	100	100	96	1.2s	5.6s	4.5s	0.1s	0.094
/act-early/milestones/4-years.html	53	96	96	100	97	1.4s	7.2s	18.0s	0.5s	0.082
/nssp/php/onboarding-toolkits/data-quality.html	94	100	100	100	100	1.4s	2.3s	4.6s	0.1s	0.001
/acip/grade/cholera-cvd-103-hgr-child-2-17-years.html	91	97	100	100	100	1.7s	2.5s	4.7s	0.2s	0.012
/mmwr/volumes/69/ss/ss6909a1.htm	64	98	96	100	71	2.1s	3.2s	2.1s	0.5s	0.287
/flu/whats-new/2023-2024-flu-heart-study.html	71	100	100	100	100	1.6s	3.0s	6.0s	0.7s	0.009
/emerging-infections-program/site.html	91	100	100	100	100	1.6s	2.8s	3.4s	0.2s	0.003
/niosh/publications/numbered/2023-123.html	70	100	100	100	34	1.6s	4.6s	4.3s	0.2s	0.181
/mmwr/preview/mmwrhtml/mm6302a5.htm	97	84	85	92	50	1.8s	2.2s	1.8s	0.1s	0.005
/traumatic-brain-injury/signs-symptoms/index.html	45	100	100	100	100	2.3s	28.1s	7.1s	0.9s	0
/thalassemia/communication-resources/initiating-regular-transfusions.html	94	100	100	100	100	1.6s	2.3s	4.1s	0.2s	0.019
/hiv/treatment/index.html	49	89	93	100	17	1.7s	13.8s	6.2s	0.2s	0.338
/mmwr/preview/mmwrhtml/00015127.htm	61	59	63	83	100	2.7s	5.5s	4.4s	0.5s	0
/mmwr/volumes/71/wr/mm7110a3.htm	59	98	96	100	67	2.9s	4.2s	2.9s	0.3s	0.335
/group-a-strep/about/strep-throat.html	65	91	100	85	50	2.2s	15.0s	7.2s	0.1s	0.009
/pulsenet/about/index.html	80	100	100	100	98	1.6s	3.4s	5.1s	0.3s	0.075
/diabetes/caring/5-questions-health-care-team.html	79	100	100	100	93	1.6s	3.5s	5.7s	0.2s	0.114
/adenovirus/about/index.html	87	100	100	100	94	1.2s	3.2s	4.0s	0.1s	0.111
/mmwr/preview/mmwrhtml/mm5644a1.htm	100	62	67	83	100	1.2s	1.3s	1.2s	0.1s	0
/niosh/bulletin/2023/cannabis-allergies.html	92	100	100	100	100	1.6s	2.0s	5.0s	0.2s	0.035
/mmwr/volumes/65/wr/mm6519a2.htm	69	95	96	92	71	2.0s	3.6s	2.1s	0.2s	0.287
/importation/index.html	75	100	100	92	100	1.6s	5.7s	4.6s	0.1s	0.002
/mmwr/preview/mmwrhtml/00000353.htm	100	62	62	83	100	0.8s	1.0s	0.8s	0.0s	0
/niosh/docs/2016-106/default.html	92	100	100	100	100	1.7s	2.2s	4.8s	0.2s	0.037
/nchs/products/databriefs/db399.htm	45	100	96	100	58	2.7s	7.4s	2.7s	0.3s	0.497
/mmwr/volumes/66/wr/mm6640a3.htm	81	95	96	92	74	2.0s	2.0s	2.1s	0.2s	0.263
/mmwr/volumes/70/wr/mm7033a2.htm	69	98	96	100	76	2.0s	4.0s	2.0s	0.3s	0.239
/readiness/php/testgame/test-pod-discussion-guide.html	71	100	100	100	100	1.2s	2.7s	5.9s	0.9s	0.012
/heat-health/es/risk-factors/la-mascotas-y-el-calor.html	93	100	100	100	100	1.2s	2.3s	5.0s	0.1s	0.035
/flu/weekly/weeklyarchives2023-2024/week29.htm	52	99	96	100	64	2.2s	6.9s	2.2s	0.2s	0.385
/nchs/pressroom/stats_of_the_states.htm	34	100	96	100	100	2.3s	31.7s	9.8s	2.8s	0
/mmwr/preview/mmwrhtml/mm6246a6.htm	95	79	85	92	50	1.8s	2.6s	1.8s	0.1s	0
/pcd/issues/2011/may/10_0163_es.htm	99	66	65	83	50	0.8s	1.3s	0.8s	0.1s	0
/mers/site.html	95	100	100	100	100	1.2s	2.0s	4.3s	0.2s	0.003
/mmwr/index2018.html	51	100	96	100	65	1.8s	6.8s	1.8s	0.3s	0.358
/mmwr/preview/mmwrhtml/00000900.htm	100	62	63	83	100	1.1s	1.1s	1.1s	0.0s	0
/mmwr/preview/mmwrhtml/00018113.htm	100	62	63	83	100	1.2s	1.3s	1.2s	0.0s	0
/pcd/issues/2021/20_0362.htm	51	100	92	100	52	1.7s	6.8s	2.1s	0.1s	0.896
/school-health-profiles/methods/2022-response-rate.html	96	100	100	100	100	1.6s	2.0s	4.2s	0.0s	0.023
/monkeypox/hcp/clinical-care/pregnancy.html	91	100	100	100	100	1.7s	2.5s	4.8s	0.2s	0.012
/mmwr/volumes/65/wr/mm6526a1.htm	74	95	96	100	72	2.0s	2.6s	2.0s	0.3s	0.283
/asthma-data/reports-publications/index.html	77	100	96	100	100	1.5s	2.9s	5.4s	0.5s	0.003
/pcd/issues/2018/18_0062.htm	47	100	96	100	54	2.1s	6.9s	2.3s	0.2s	0.7
/pcd/issues/2008/jul/07_0138_zhs.htm	98	66	65	83	50	0.9s	1.2s	0.9s	0.1s	0
/scientific-integrity/php/human-subjects-protection	93	100	100	100	100	1.7s	2.5s	4.2s	0.1s	0.013
/mmwr/volumes/67/wr/mm6716a3.htm	76	98	96	100	76	2.0s	2.7s	2.0s	0.3s	0.239
/vaccines-for-children/about/index.html	79	100	100	100	96	1.6s	4.3s	4.6s	0.1s	0.092
/orr/responses/multistate-meningitis-outbreak.html	81	100	96	100	94	1.3s	2.6s	5.4s	0.3s	0.111
/niosh/docs/2019-118	83	100	100	100	43	1.7s	3.4s	5.7s	0.1s	0.114
/flu/prevention/index.html	66	91	100	85	50	2.3s	8.7s	6.7s	0.1s	0.009
/think-test-treat-tb/about/index.html	62	96	96	100	93	1.2s	5.8s	5.8s	0.3s	0.113
/niosh/docs/2021-120/default.html	87	100	100	100	39	1.3s	2.3s	5.7s	0.0s	0.145
/nhsn/ltc/newsletters/dec19-newsletter-ltc.html	62	100	96	100	61	2.0s	3.8s	2.0s	0.3s	0.441
/about/divisions-offices/ophdst.html	94	100	100	100	100	1.6s	2.0s	4.7s	0.1s	0.043
/vaccines/hcp/administration/before.html	65	91	100	85	50	2.2s	12.8s	7.2s	0.1s	0.009
/mmwr/preview/mmwrhtml/mm5315a7.htm	100	62	65	83	100	0.9s	1.1s	0.9s	0.1s	0
/niosh/publications/numbered/2005-138.html	77	100	100	100	100	1.2s	3.9s	5.3s	0.3s	0.003
/niosh/npptl/topics/respirators	69	100	100	100	100	1.7s	7.9s	5.2s	0.2s	0.003
/tularemia/about/index.html	81	100	100	100	94	1.6s	3.7s	4.8s	0.1s	0.106
/mmwr/preview/mmwrhtml/mm5908a4.htm	94	79	85	92	50	1.5s	2.9s	1.5s	0.1s	0
/mmwr/volumes/71/rr/rr7101a1.htm	58	98	96	100	66	2.0s	3.6s	2.0s	0.6s	0.356
/nchs/pressroom/calendar/2026_schedule.htm	47	93	96	92	14	2.4s	7.6s	3.6s	0.3s	0.371
/mmwr/preview/mmwrhtml/mm5301a1.htm	100	62	65	75	100	0.8s	1.1s	0.8s	0.1s	0
/niosh/docs/2005-124	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
/mmwr/volumes/69/wr/mm6913a1.htm	73	98	96	100	71	2.0s	2.6s	2.0s	0.3s	0.287
/pcd/issues/2008/jul/07_0104.htm	100	70	65	83	50	1.0s	1.1s	1.0s	0.1s	0
/media/es/releases/2026/nuevo-retiro-del-mercado-en-brote-de-salmonella-vinculado-a-suplementos-alimenticios-que-contienen.html	85	100	100	100	100	1.6s	2.9s	5.7s	0.2s	0.021
/niosh/publications/numbered/2014-127.html	72	100	100	100	100	1.3s	26.6s	4.5s	0.1s	0.017
/mmwr/volumes/69/wr/mm6914a5.htm	60	98	96	100	66	2.1s	3.5s	2.1s	0.5s	0.355
/mmwr/preview/mmwrhtml/mm5506a1.htm	100	62	65	83	100	0.8s	1.4s	0.8s	0.0s	0
/monkeypox/php/monitoring/index.html	94	100	100	100	100	1.6s	2.3s	4.1s	0.2s	0.012
/bird-flu/spotlights/bird-flu-surveillance.html	94	100	100	100	100	1.2s	2.1s	4.8s	0.1s	0.006
/pinkbook/hcp/table-of-contents/chapter-18-poliomyelitis.html	94	100	100	100	100	1.7s	2.3s	3.9s	0.1s	0.005
/asthma/nhis/2019/table6-1.htm	57	96	100	100	62	2.0s	5.0s	2.0s	0.2s	0.421
/mmwr/preview/mmwrhtml/00001615.htm	100	62	62	83	100	1.1s	1.2s	1.1s	0.1s	0
/schistosomiasis/about/index.html	66	91	100	85	50	2.1s	14.4s	6.5s	0.1s	0.009
/mmwr/preview/mmwrhtml/mm6425a8.htm	83	84	85	92	50	1.6s	4.0s	4.1s	0.1s	0
/water-emergency/about	93	100	100	100	100	1.2s	2.6s	5.0s	0.1s	0
/mmwr/volumes/74/wr/mm7412a3.htm	55	98	96	100	100	6.6s	32.0s	6.8s	0.2s	0
/botulism/php/national-botulism-surveillance	82	100	100	100	96	1.2s	3.3s	5.6s	0.2s	0.089
/niosh/heat-stress/es/recursos/comunicar.html	87	100	100	100	100	1.6s	2.1s	6.3s	0.3s	0.008
/brfss/data_documentation/index.htm	57	100	96	100	67	1.8s	2.9s	2.1s	0.9s	0.337
/mmwr/preview/mmwrhtml/mm6012a1.htm	97	79	85	92	50	1.8s	2.3s	1.8s	0.1s	0
/mmwr/preview/mmwrhtml/mm5044a2.htm	100	62	65	83	100	0.8s	1.1s	0.8s	0.1s	0
/acip/meetings/presentation-slides-october-25-26-2023.html	92	100	100	100	100	1.2s	2.0s	4.7s	0.2s	0.011
/lyme/data-research/facts-stats/surveillance-data-1.html	65	91	100	85	50	2.2s	15.3s	7.3s	0.1s	0.009
/healthy-youth/communication-resources/index.html	50	100	100	100	70	1.3s	16.8s	7.7s	0.2s	0.305
/mmwr/preview/mmwrhtml/00051740.htm	100	62	62	83	100	0.9s	0.9s	0.9s	0.1s	0
/mmwr/preview/mmwrhtml/00046958.htm	73	62	63	83	100	1.6s	4.6s	2.4s	0.4s	0
/mmwr/preview/mmwrhtml/mm4837a3.htm	100	62	67	83	100	1.1s	1.1s	1.1s	0.1s	0
/mmwr/preview/mmwrhtml/mm4943a2.htm	100	62	67	83	100	1.1s	1.6s	1.1s	0.1s	0
/mmwr/preview/mmwrhtml/mm5531md.htm	93	59	62	83	100	0.9s	3.2s	1.1s	0.1s	0
/acip/evidence-to-recommendations/nirsevimab-season2-rsv-infants-children-etr.html	87	100	100	100	100	1.8s	3.2s	4.6s	0.2s	0.033
/mmwr/volumes/65/wr/mm6502a3.htm	71	98	96	100	72	2.0s	3.3s	2.1s	0.3s	0.277
/mmwr/preview/mmwrhtml/mm5651a7.htm	99	51	65	75	48	0.9s	1.1s	0.9s	0.0s	0.067
/brfss/acbs/2006/prevalence_tables/table11b.html	48	96	96	92	51	2.3s	5.6s	2.3s	0.2s	1.259
/toxocariasis/site.html	93	100	100	100	100	1.3s	2.1s	5.1s	0.2s	0.019
/mosquitoes/mosquito-control/community/adulticides.html	68	100	96	100	96	1.2s	5.0s	7.3s	0.2s	0.089
/dpdx/clonorchiasis/index.html	54	90	100	92	36	4.3s	31.0s	4.3s	0.2s	0.165
/locs/php/clcr-calls/2020/2020-05-11.html	85	100	100	100	100	1.2s	3.5s	4.8s	0.2s	0.042
/brfss/acbs/2020/prevalence_tables/table9_LLCP.html	51	100	100	100	53	2.4s	3.2s	2.4s	0.6s	0.779
/mmwr/volumes/73/ss/ss7307a1.htm	66	98	96	100	76	2.0s	2.9s	2.0s	0.6s	0.239
/niosh/docs/mining/works/coversheet1118.html	68	100	100	100	50	1.2s	10.8s	6.3s	0.1s	0.042
/botulism/diagnosing-treating/index.html	83	100	100	100	94	1.5s	3.3s	4.2s	0.2s	0.106
/pcd/issues/2006/jan/05_0109.htm	99	70	67	83	50	1.3s	1.5s	1.3s	0.1s	0
/niosh/ptd/awards	78	100	100	92	99	1.4s	4.9s	4.3s	0.1s	0.065
/pcd/issues/2009/jan/08_0006_fr.htm	100	66	67	83	50	1.1s	1.4s	1.1s	0.1s	0
/media/index.html	76	100	100	92	100	1.2s	3.4s	4.5s	0.5s	0.018
/niosh/docs/wp-solutions/2017-113	91	96	100	100	50	1.2s	2.8s	4.2s	0.2s	0.007
/psittacosis/php/laboratories/index.html	65	100	100	100	100	1.6s	46.7s	8.5s	0.2s	0.012